769 related articles for article (PubMed ID: 33200955)
1. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
Gael M; Adam T; Mariano-Bourin M; Bursztejn AC
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1541-1551. PubMed ID: 35569006
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
4. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
Zhang Z; Li S; Wang Y; Zhao J
An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
[TBL] [Abstract][Full Text] [Related]
6. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
9. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
10. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab for the treatment of prurigo nodularis: A systematic review.
Cao P; Xu W; Jiang S; Zhang L
Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
[TBL] [Abstract][Full Text] [Related]
13. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Dupilumab in Pediatric Patient With Prurigo Nodularis-Like Atopic Dermatitis.
Yiling Y; Ali K; Jiayang D; Qiu Y; Kai G; JinPeng S; Tianci X; Min C; Menghua L; Liming W
Dermatitis; 2023; 34(2):162-163. PubMed ID: 36917530
[No Abstract] [Full Text] [Related]
18. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H; Sadik CD; Ludwig RJ; Thaçi D; Boch K
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189381
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
Tanis R; Ferenczi K; Payette M
J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
